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Autism spectrum disorders (ASDs) constitute a group of severe neurodevelopmental conditions with com-
plex multifactorial etiology. In order to explore the hypothesis that submicroscopic genomic rearrangements
underlie some ASD cases, we have analyzed 96 Spanish patients with idiopathic ASD after extensive clinical
and laboratory screening, by array comparative genomic hybridization (aCGH) using a homemade bacterial
artiﬁcial chromosome (BAC) array. Only 13 of the 238 detected copy number alterations, ranging in size
from 89 kb to 2.4 Mb, were present speciﬁcally in the autistic population (12 out of 96 individuals, 12.5%).
Following validation by additional molecular techniques, we have characterized these novel candidate
regions containing 24 different genes including alterations in two previously reported regions of chromo-
some 7 associated with the ASD phenotype. Some of the genes located in ASD-speciﬁc copy number variants
act in common pathways, most notably the phosphatidylinositol signaling and the glutamatergic synapse,
both known to be affected in several genetic syndromes related with autism and previously associated
with ASD. Our work supports the idea that the functional alteration of genes in related neuronal networks
is involved in the etiology of the ASD phenotype and conﬁrms a signiﬁcant diagnostic yield for aCGH,
which should probably be included in the diagnostic workup of idiopathic ASD.
INTRODUCTION
Autism spectrum disorders (ASDs) (OMIM: 209850) are a
group of severe neurodevelopmental conditions, referred to a
broader extent as pervasive developmental disorders, charac-
terized by a triad associating impairments in social inter-
actions, communication deﬁcits and restricted repetitive and
stereotyped behaviors and interests with an onset in infancy
or early childhood (before 3 years). The estimated prevalence
of ASD was 2–5/10 000 with a ratio four times higher in
males than in females (1). In the last decades, a signiﬁcant
increase (6–10-fold) of prevalence has been noticed, partially
explained by improvements in case ascertainment, making
ASD a public health priority (2).
There is strong evidence for a genetic etiology of ASD
given that the concordance rates in monozygotic twins are
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are 10% (3). ASD is considered to have a complex multifac-
torial etiology involving many genes. These genetic factors
would contribute to the neurobiological alterations responsible
for the ﬁnal array of autistic phenotypes.
ASD is found in association with other conditions in 10%
of cases, including known genetic disorders such as fragile-X
syndrome, tuberous sclerosis and cytogenetic abnormalities,
mostly duplications at 15q11.13 on the maternally inherited
chromosome (Prader–Willi/Angelman syndrome region) and
terminal deletions of chromosomes 2q or 22q (4,5). Genome-
wide linkage and candidate–gene association studies have
found evidence for autism susceptibility loci on more than
20 different chromosome regions including 1p, 2q, 5q, 7q,
15q, 17q 19p and Xq, although only a few of them have
been replicated (6). Single-gene mutations in SHANK3 (gene
ID: 85358) (22q13.3), NLGN3/NGLN4 (gene ID: 54413/
57502) (Xq13/Xp22.33) and NRXN1 genes (gene ID: 9378)
(2p16) have been described as causative of ASD in a small
number of patients. Additional studies and homozygosity
mapping in inbred families have also revealed genes with
strong susceptibility to autism, such as the neurexin family
member CNTNAP2 (gene ID: 26047) among others (7–13).
Recent reports showed that submicroscopic copy number var-
iants (CNVs) can also have a relevant role in autism (14,15)
with de novo germline variants as a signiﬁcant risk factor in
sporadic forms of ASD (16). A speciﬁc CNV at 16p11.2 has
been found in 1% of the ASD patients as well as in individ-
uals with mental retardation (17–19). In addition, the recipro-
cal duplication of several deletion syndromes, dup7q11.23,
dup17p11.2 and dup22q11, can lead to a phenotype of
mental retardation and ASD (20–22). All these data further
indicate the genetic heterogeneity of ASD with different
modes of inheritance and different contribution of de novo
and inherited variants in individual families.
Given that the cause of ASD in the majority of patients is
still unknown and the fact that many genomic regions have
been associated with the disorder, genome-wide screening
methods seem to be indicated for the identiﬁcation of affected
regions and speciﬁc CNVs that could be associated to the
disease. We have analyzed 96 Spanish patients with idiopathic
ASD after ruling out most known genetic causes, using a
homemade BAC microarray for comparative genomic hybrid-
ization (aCGH) (23). With this approach, we have identiﬁed
13 novel ASD-speciﬁc copy number changes including two
rearrangements in genomic regions previously associated
with the ASD phenotype, such as 7q11.22 and 7q31.33–
32.1. Interestingly, a signiﬁcant proportion of the 24 different
genes located in these 13 loci are strong functional candidates
for ASD, involved in common or related neuronal signaling
networks.
RESULTS
We selected for the study 96 Spanish patients (12 females and
84 males, ratio: 1/7) with idiopathic ASD after extensive clini-
cal and laboratory screening. ASD was conﬁrmed in all cases
using the Autism Diagnostic Interview-Revised (ADI-R). All
patients had been examined by neurologists and clinical
geneticists and also had an extensive negative laboratory
workup, including standard karyotyping, fragile X molecular
testing, subtelomeric and targeted multiplex ligation probe
ampliﬁcation (MLPA) screening (probes for the regions
1p36, 2q37, 7q11.23, 15q11–q13, 16p11.2, 17p11.2,
22q11.2 and 22q13.3), as well as metabolic studies in some
cases when clinically indicated (Gener et al., submitted).
Autism-speciﬁc CNVs
We detected gains and losses of a total of 238 BACs in the
ASD samples with the hot-spot-BAC-array (HSBA) aCGH:
194 of these CNVs had been previously described as puta-
tively polymorphic in the population by other authors (http://
projects.tcag.ca/variation) and 18 more were also detected in
our control samples (n ¼ 52). We considered that two CNVs
could be the same when they overlapped in .70% of their
predicted genomic content. The remaining 26 variants cover-
ing 21 genomic regions (5 deletions, 15 ampliﬁcations and 1
detected as both) were present speciﬁcally in the ASD popu-
lation and were then considered as possibly pathogenic (Sup-
plementary Material, Table S1). These CNVs ranged in size
from 89 kb to 2.4 Mb. On average, we detected 9.8 CNVs
per individual in ASD samples and 12.4 in controls, with no
signiﬁcant difference.
To deﬁne the experimental variability of the hybridization
signal of the BACs detecting CNVs, we performed a boxplot
analysis of the log2 ratios in all control samples; 7 out of 26
BACs showed high signal dispersion, suggesting possible
false-positive results (Supplementary Material, Fig. S1).
In order to validate, better deﬁne and determine whether the
novel rearrangements were inherited or de novo, we then tar-
geted these 21 putative pathological variants with additional
molecular technologies: MLPA assays with speciﬁc synthetic
probes and oligo aCGH (Agilent 44k or 244K) or SNP array
(Illumina 370). Using these tools, we conﬁrmed the CNVs
in 13 regions affecting 12 patients, and we deﬁned the size
and nature of the rearrangement, being complex in some
cases (Table 1, Fig. 1). A total of eight CNVs detected with
the BAC array were not conﬁrmed by the other methods, six
of them corresponding to single BACs with high dispersion
of the signal (Supplementary Material, Fig. 1). The MLPA
assays conﬁrmed that the rearrangements were inherited in
the ﬁve patients for whom both parental samples were avail-
able. Unfortunately, samples from one or both parents of the
remaining seven patients were unavailable and we could not
determine whether their CNVs were de novo or inherited
(Table 1).
We then screened our entire cohort of autistic samples (n ¼
215) and controls (n ¼ 120) with a homemade MLPA panel
containing probes targeting each of the CNVs found by
aCGH. We did not ﬁnd rearrangements in any additional
patient or control individual. We also searched the database
of Genomics Variants (http://projects.tcag.ca/variation) for
similar rearrangements, using the data from controls (n .
1800) that had been analyzed by high-density oligo arrays
with enough probe coverage in the regions (more than 10
probes per locus) (24–26). Although there was some partial
overlap at three loci with CNVs reported in population con-
trols (Supplementary Material, Table S1), none was of the
1796 Human Molecular Genetics, 2009, Vol. 18, No. 10Table 1. Description of the conﬁrmed CNVs affecting each of the 12 patients with ASD, including the BAC ID, chromosomal location, size, CNV type, validation methods and gene content
Sample Gender BAC ID Cytoband CNV Validation Start End Length
(kb)
Origin MLPA
probe
Gene content
AUT21 F RP11-125A7 chr13q14.11 Gain MLPA þ Illumina 41 003 320 41 418 753 415.433 MAT KIAA0564 KIAA0564
AUT24 M RP11-55L3
a chr4q26 Gain MLPA þ Agilent 117 191 242 119 614 346 2423.104 MAT TRAM1L1 NDST3, PRSS12, TRAM1L1
RP11-458P15
RP11-61N14
RP11-335K15
a
RP11-778G8
a
RP11-510D4
a
RP11-750O22
a
RP11-366I1
a
CTD-201L19
a
RP11-630F19
a
AUT31 M RP1-117N3 chr1p35.1 Loss Agilent 33 158 375 33 263 299 104.924 NA RNF19B, AK2
AUT42 M RP11-140C4 chr2q33.3 Gain MLPA þ Illumina 208 759 831 208 849 748 89.917 NA PIP5K3 C2orf80, IDH1, PIP5K3
AUT45 F RP11-266G18 chr21q21.2 Gain Illumina 25 518 184 25 708 178 189.994 NA No genes
AUT84 M RP11-510O20
a chr7q31.33–
q32.1
Gain MLPA þ Agilent 125 672 999 126 255 215 582.216 NA GRM8 GRM8
RP11-105E3
RP11-432H11
RP11-21K15
RP11-475H14
a
CTD-210M22
a
RP11-290P11
a
AUT91 M RP11-99M10 chr18q12.1 Gain MLPA þ Illumina 10 127 382 10 594 362 466.98 NA NAPG APCDD1, NAPG
AUT96 M RP11-21N8 chr3q21.3 Gain MLPA þ Agilent 131 845 264 131 974 345 129.081 NA PIK3R4 COL6A6, PIK3R4
RP11-575M4 chr7q11.22 Gain MLPA þ Agilent 69 630 362 69 955 721 325.359 AUTS2 AUTS2
AUT138 M RP11-281H14 chr11q14.1 Loss MLPA þ Illumina 84 032 216 84 276 593 244.377 NA DLG2 DLG2
AUT150 M RP11-47L17
a
RP11-158F10
RP11-194K9
chr5q35.3 Gain MLPA þ Agilent 177 501 908 177 688 820 186.912 PAT AGXT2L2 COL23A1, AGXT2L2, GMCL1L,
HNRNPAB, NOLA2, RMND5B
AUT186 M RP11-239E10 chr1q41 Loss MLPA þ Illumina 221 401 766 221 501 748 99.982 PAT SUSD4 SUSD4
AUT195 M RP11-107B3 chr3q22.3 Gain MLPA þ Illumina 139 934 042 140 070 771 136.729 PAT PIK3CB PIK3CB
The ﬁnal CNV size estimate is based on oligo/SNP array data.
F, female; M, male; NA, not available; MAT, maternally inherited; PAT, paternally inherited.
aBACs overlapping with polymorphic CNVs described in controls.
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7size and gene content of those found in ASD patients. Thus,
the CNVs found are unique in each family and very rare or
absent in the general population.
More detailed phenotype data for the 12 ASD patients with
speciﬁc rearrangements are shown in Table 2.
Candidate ASD genes and pathways
We considered as candidates all genes located in the
ASD-unique rearranged regions that were validated with
additional molecular techniques—a total of 24 genes (Sup-
plementary Material, Table S2). Only 2 out of 24 were
completely deleted (AK2 and RNF19B) (gene IDs: 204/
127544), 11 out of 24 completely duplicated and the remain-
ing 11 out of 24 partially altered or disrupted.
Two of the detected alterations lie in regions of chromo-
some 7 previously related with ASD, 7q11.22 and 7q31.3,
containing or disrupting a single candidate gene per rearrange-
ment, AUTS2 (gene ID: 282553) and GRM8 (gene ID: 2918),
respectively (Fig. 1). The remaining 11 CNV regions detected
in ASD patients affected novel regions.
We then analyzed the data set of genes in ASD-related
CNVs, using different computational resources [Ingenuity
Pathway Analysis (IPA), ConsensusPathDB, KEGG], to
obtain a general overview of their most relevant functions.
Among the different functions encoded by those genes, the
inositol and phosphatidylinositol-3-OH kinase (PI3K)
signaling pathways were signiﬁcantly overrepresented
(P ¼ 1.64E þ 06) (Supplementary Material, Table S3). Inter-
estingly, in addition to the two genes directly involved in
the PI3K pathway (PIK3CB and PIP5K3) (gene IDs: 5291/
200576), at least four other genes included in the ASD-speciﬁc
CNVs encode proteins that act either upstream or downstream
of PI3K: PIK3R4, DLG2, AGXT2L2 and GRM8 (Fig. 2 and
Supplementary Material, Table S2), in related pathways such
as the toll-like receptor signaling, the regulation of autophagy
or the neuroactive ligand–receptor interaction. Therefore, at
least 6 of the 13 ASD-speciﬁc CNVs affect genes with a
role in related pathways, whereas only 4 of the remaining
212 non-ASD-speciﬁc CNVs contained genes in those path-
ways (signiﬁcant Z-test with a 99% conﬁdence interval).
This ﬁnding strongly suggests a potential contribution of the
identiﬁed ASD-speciﬁc CNVs to the ASD phenotype.
Figure 1. Speciﬁc rearrangements detected in ASD patients. Each subﬁgure shows, under the patient’s identiﬁer and chromosome number, a scheme of the
genomic region containing the CNV. From top to bottom: (i) chromosomal scale (Mb), (ii) G-band of the chromosome, (iii) regional CNVs described in
public databases (http://projects.tcag.ca/variation), (iv) genes in the interval, (v) probes of the Illumina or Agilent arrays, (vi) MLPA probes, (vii) probes of
the BAC array and (viii) plot with the results of the oligo or SNP array hybridization showing the deleted (below 0.4) or duplicated (above 0.4) intervals
ﬂanked by red dots.
1798 Human Molecular Genetics, 2009, Vol. 18, No. 10To explore whether the same pathways were also overrepre-
sented in disease-speciﬁc CNVs detected in ASD samples by
other studies (15,16,27,28), we downloaded the genes in
those CNVs and analyzed their functional annotation by the
ConsensusPathDB. We obtained a total of 2901 genes from
the available data. Using the pathway-based sets, we observed
the same pathways clearly overrepresented among those
genes, being on top the toll-like receptor signaling, the regu-
lation of autophagy and the mTOR signaling (P , 0.001),
among others (Supplementary Material, Table S4). PI3K sig-
naling is key in the mTOR upstream activation process
(Fig. 2).
Non-speciﬁc CNVs
We also analyzed the CNVs found in our ASD patients that
had also been described as rare variants in controls (reported
in ,1% of controls) for the presence of genes belonging to
the same or related pathways. Interestingly, three patients
showed a gain-type CNV in the 15q13.3 region that included
the CHRNA7 gene (gene ID: 1139). Given that the ﬂanking
BACs in the array gave normal signal, this duplication likely
corresponds to a 500 kb interval (29, 8–30, 3 Mb of
chromosome 15) located between segmental duplications
that has also been found in 1% of the general population
(http://projects.tcag.ca/variation). In addition, an autistic
patient showed a gain-type CNV, including the PDPK1 gene
(gene ID: 5170), and another case had a gain-type CNV,
including the RAF1 gene (gene ID: 5894). By MLPA analysis,
we found that the CNVs in these ﬁve cases were inherited
from unaffected progenitors. The RASSF5 gene (gene ID:
83593) as well as ﬁve RAB family members related to the
same signaling pathway were also present in non-ASD
exclusive CNVs.
DISCUSSION
The use of high-throughput genomic techniques has demon-
strated to be a powerful strategy for the detection of
genomic abnormalities associated with ASD (15,16,27). In
our hands, the use of a BAC aCGH has allowed the identiﬁ-
cation of speciﬁc regions altered in copy number in a signiﬁ-
cant proportion of our autistic population, 12 out of 96 cases
(12.5%), being inherited from a normal parent in all ﬁve
cases with parental samples available. Some of these regions
were already reported to harbor ASD genes by either linkage
and association studies or by the ﬁnding of chromosomal
translocation breakpoints in ASD patients (11,29–31). Other
altered regions in our autistic population that could be
linked to the pathological phenotype have also been found
as rare variants in relatives and/or non-autistic population.
The incomplete penetrance of these rare inherited CNVs
could be due to several factors including interaction with
other genetic or epigenetic alterations, environmental modi-
ﬁers or the unmasking of recessive alleles. This is probably
the expected situation in a multifactorial and complex
disease such as ASD, a group of different conditions with
overlapping phenotype generated each from a single or,
more frequently, a combination of genetic changes with poss-
ible environmental contribution as well. Therefore, genetic
studies should search for the different multifactorial
combinations.
The CNVs found in ASD patients could be merely passen-
ger changes or have a driver contribution to the autistic pheno-
type should they lead to disruption or deregulation of relevant
genes. We initially focused our interest in the regions that
were altered only in our autistic population and had not
been found in controls. We detected and conﬁrmed 13 chro-
mosomal alterations affecting 12 of our patients. Since we
had excluded from the study ASD patients with non-idiopathic
ASD after previous extensive clinical and laboratory screening
with targeted MLPA analyses for subtelomeric and known
rearrangements, the yield of the aCGH in detecting novel
CNVs potentially related with the ASD phenotype is quite sig-
niﬁcant—12.5%. Only 3 were genomic losses, whereas 10
changes were genomic gains.
Two of the ASD-related CNVs identiﬁed map to regions of
strong linkage with ASD on chromosome 7, 7q11.22 and
7q31.3, and contain genes already proposed as candidates,
AUTS2 and GRM8, respectively. The AUTS2 gene, encoding
Table 2. Phenotype data of the 12 patients with autism spectrum and speciﬁc rearrangements
Patient Sex Diagnosis Mental
retardation
Dysmorphism Seizures Aggressiveness Other features
AUT21 F Autism Moderate No No No
AUT24 M Autism Moderate No No No Neurosensorial deafness (65 dB); diaphagmatic hernia
(Bochdalek)
AUT31 M Autism Severe No No No
AUT42 M Autism Severe No No Yes
a
AUT45 F Autism Severe No Yes Yes Subcortical brain atrophy
AUT84 M Autism Severe No Yes No Hyperekplexia or startle disease
AUT91 M Autism Severe No No No
AUT96 M Autism Severe No No Yes
a
AUT138 M Autism Severe No No No Hypermetropy (þ5d), short stature (22DS)
AUT150 M Autism Moderate No No No Obsessive-compulsive disorder
AUT186 M PDD Mild Yes No No Retrognatia
AUT195 M Autism Mild No No No Unilateral neurosensorial deafness
PDD, pervasive developmental disorder.
aOccasional self-injurious behavior.
Human Molecular Genetics, 2009, Vol. 18, No. 10 1799a large protein of unknown function, was found disrupted at
the 7q11.2 breakpoint of different balanced translocations
and inversion in ASD patients, as well as in unrelated patients
with severe mental retardation (11,29,30). Genetic variants in
the GRM8 gene, coding for the glutamatergic receptor 8, have
also shown signiﬁcant association with ASD (31). GRM8 is a
strong functional candidate given that GRM8 overactivity in
the lateral amygdala leads to the inhibition of synaptic trans-
mission impairing learned fear acquisition, a feature present
in ASD (32). It has also been shown that the lateral amygdala
has an abnormal growth pattern and signiﬁcantly fewer
neurons in autistic patients (33). Interestingly, the patient
with the rearranged GRM8 gene presented, in addition to
ASD and severe mental retardation, an abnormal startle
response to tactile stimuli and a diagnosis of hyperekplexia
(OMIM: 149400). Dysfunction of the glutamatergic synapse
in ASD is also supported by the ﬁnding of mutations in
additional genes somehow involved in glutamatergic trans-
mission, such as NLGN3, NLGN4, NRXN1, SHANK3,
CNTNAP2 and even FMR1 (gene ID: 2332), the gene respon-
sible for the fragile X syndrome (FXS, OMIM: 300624).
Out of the genes affected by the remaining ASD-related
CNVs, we have highlighted some genes with causative poten-
tial considering their biological role. The most striking ﬁnding
is that two of those genes directly participate in the PI3K sig-
naling pathway (PIP5K3 and PIK3CB) and a third gene
(PIK3R4) is highly related. Signaling by phosphorylated
species of phosphatidylinositol regulates diverse cellular pro-
cesses including membrane trafﬁcking, cytoskeletal reorganiz-
ation (34) and sex-dependent synaptic patterning (35), having
also a role in glutamatergic and nicotinic neurotransmission
and mTOR activation (36). The putative association of this
pathway with the autistic phenotype has been previously pro-
posed by other reports (31,37,38). Transmission disequili-
brium test and haplotype analyses of regions of previous
linkage to autism demonstrated that polymorphisms in the
INPP1, PIK3CG and TSC2 genes (gene IDs: 3628/5294/
7249), all in the PI3K pathway, are in linkage disequilibrium
with autism (39).
Although the functional consequences of these three CNVs
are still unknown, we propose that they all might lead to the
upregulation of the PI3K pathway. The ﬁrst CNV includes a
partial duplication of PIK3CB affecting the N terminal part
of the gene that contains the p85-negative regulatory subunit-
binding site and the RAS-binding site but not the catalytic C
terminal domain. A deletion mutant of PIK3CB lacking the
entire p85-binding domain has been previously described
that efﬁciently activated PI3K signaling (40). The second
ampliﬁcation-type CNV includes the promoter region of
PIP5K3. It is logical to propose that overfunction might be
related to ASD, since heterozygous hypomorphic mutations
of this gene cause the Francois–Neetens ﬂeck corneal dystro-
phy (OMIM: 121850) (41), a phenotype conﬁned to the cornea
that was not observed in our patient. A third CNV contains
Figure 2. Schematic representation of the glutamatergic synapse and the postsynaptic neuronal signaling pathways relevant to ASD, with the putative locationo f
the proteins encoded by the genes affected by the CNVs detected [(1) PIK3CB, (2) PIK3R4, (3) PIP5K3, (4) DLG2, (5) RAF1, (6) PDPK1, (7) CHRNA7, (8)
AGXT2L2, (9) GRM8 and (10) NAPG]. The interrupted arrows show the abnormal function in three monogenic disorders associated with ASD: NF1, BRRS
and TSC.
1800 Human Molecular Genetics, 2009, Vol. 18, No. 10a complete duplication of the PIK3R4 gene, coding for a
highly conserved protein from yeast to humans that interacts
with PIK3C3 in vivo to regulate the protein trafﬁcking
required for PI3K activity (42).
Interestingly, we found additional genes related to the same
pathway in CNVs detected in ASD patients; initially discarded
because they had been reported in normal controls as rare var-
iants. The duplication-type CNV containing the PDPK1 gene
in one patient might somehow alter the PI3K signaling
pathway since PDPK1 directly phosphorylates AKT (Fig. 2).
The duplication-type CNV observed in three patients at
15q13.3 containing the CHRNA7 gene which codes for the
alpha7 nicotinic acetylcholine receptor could also contribute
to pathway disregulation because the cytoplasmatic signal
transmission of this receptor involves PI3K (36). Microdele-
tion and microduplication of a larger interval in this region
have recently been described as a novel syndrome with incom-
plete penetrance and variable phenotype including mental
retardation, autistic features, epilepsy and other neuropsychia-
tric disorders (43).
We sought further evidence of genetic variation in the PI3K
pathway in previously published data of autistic populations
(15,16,27,28). Three other genes directly related to this
pathway were found in ASD-associated rearrangements: ﬁve
ASD patients had a loss of GAB2 (gene ID: 9846), coding
for a PI3K-negative regulator in the TCR signaling pathway,
one case had a gain of PIK3C2G (gene ID: 5288) and one
case had a PIP5K1B (gene ID: 8395) gene disruption by a
balanced translocation (15).
Additional evidence supporting a role of the PI3K signaling
pathway in autism comes from several well-characterized
genetic diseases frequently comorbid with ASD, such as tuber-
ous sclerosis (TSC, OMIM: 191100), neuroﬁbromatosis 1
(NF1, OMIM: 162200), Bannayan–Riley–Rubalcaba syn-
drome (BRRS, OMIM: 153480) and FXS (44). The prevalence
of autism in patients with TSC is higher than in any other con-
dition (43–86%) (45). The TSC genes, TSC1 and TSC2, code
for proteins that act downstream the PI3K signaling pathway
downregulating mTOR (Fig. 2). As an integrator of external
stimuli, a tight regulation of mTOR activity promoting cell
growth, survival and proliferation is required for neural devel-
opment (46,47). BRRS patients with PTEN mutations may
also show ASD-like phenotype. In addition, Pten KO mice
show macrocephaly, socialization problems and exaggerated
responses to sensory stimuli, along with abnormal neurons
with dendritic hypertrophy (37). PTEN acts as a negative reg-
ulator of the PI3K signaling pathway, and overactivity of PI3K
could overcome the PTEN-negative control (Fig. 2). NF1 has
also been associated with high risk for ASD, suggesting
related etiologies for both disorders (48). NF1 is due to a
reduction of neuroﬁbromin activity, a tumor-suppressor
protein with RAS GTPase activity that attenuates the mitogen-
activated protein kinase and PI3K pathways (49). Mice that
lack neuroﬁbromin in cortical neurons and astrocytes fail to
form cortical barrels in the somatosensory cortex (50). RAS
also activates the RAF1 kinase, included as a gain-type
CNV in one of our ASD patients and his mother, as well as
in 2 out of 506 controls (24). Finally, 33% of FXS patients
fulﬁll criteria for ASD. FXS is caused by the silencing of
FMR1, coding for FMRP, a negative regulator of mRNA
translation. The loss of FMRP in FXS leads to mGluR-
dependent LTD increase, which, at the same time, is sensitive
to PI3K inhibitors (51).
The PI3K signaling pathway is one of the postsynaptic
transductors of glutamate neurotransmission. The glutamater-
gic neurotransmission has been repeatedly implicated in
some of the pathogenic mechanisms of ASD (52–54). In
addition to the evidence coming from the patient with the
GRM8 alteration, another ASD case showed a disruption of
the DLG2 gene which codes for PSD93, a protein that med-
iates tyrosine-phosphorylation of the N-methyl-D-aspartic
acid (NMDA) receptors by Fyn (55). This phosphorylation
upregulates NMDA receptor (NMDAR) function and is also
needed for its interaction with PI3K (56). Therefore, DLG2
deletion might cause a reduction in NMDAR ability to trans-
duce signaling through PI3K. Another putative candidate is
the duplication of the NAPG gene coding for the
N-ethylmaleimide-sensitive factor attachment protein
gamma. NAPG interacts with syntaxin 8 and is required for
vesicular transport between the endoplasmic reticulum and
the Golgi apparatus to control membrane fusion (57).
Finally, the gain of AGXT2L2 gene copy number, seen in
one of our patients (AUT150), also has a potential role per-
turbing neurotransmission. This gene codes for a glycine bio-
synthesis enzyme. Glycine, in addition to its direct role as
neurotransmitter, is a necessary cofactor for glutamate action
through the NMDAR (58).
Local protein synthesis in neuronal dendrites is critical for
synaptic plasticity. However, the signaling cascades that
couple synaptic activation to dendritic protein synthesis in
live neurons are not fully understood although various sub-
types of glutamate receptors and the PI3K/mTOR signaling
have been demonstrated to have a prevalent role in the
control of synaptic activity-induced dendritic protein synthesis
in hippocampal neurons. Our ﬁnding of multiple genes in
these pathways affected in copy number in ASD patients
further supports the hypothesis that ASD can be caused, at
least in some cases, by perturbation of the regulatory mechan-
isms of protein synthesis in the dendrites.
The diagnosis of autism or ASD is still based on beha-
vioral criteria that do not allow differentiating among the
underlying pathologies. The ﬁnding of multiple uncommon
ASD-related CNVs, each in a speciﬁc patient, further reﬂects
the complexity and multifactorial nature of the ASD pheno-
type. The search for genetic and genomic variation along the
whole genome is still badly needed to better ascertain the
genetic background of autistic phenotypes. Given the detec-
tion yield of aCGH technologies in our and other’s experi-
ence, it should probably be included in the diagnostic
workup of idiopathic ASD, despite that genetic counseling
may be difﬁcult since many of the rearrangements detected
can also be present in asymptomatic progenitors. In addition,
more focused studies on genetic and epigenetic variations of
speciﬁc pathways using the available higher resolution
genomic technologies could lead to a better deﬁnition of
molecular signatures, being the basis for an improved diag-
nosis and the ultimate development of speciﬁc therapeutic
targets. The glutamatergic neurotransmission and the PI3K
signaling pathway appear among the candidates for this
approach.
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Patients
We have studied 96 Spanish patients (74 children followed in
the neurology clinic and 22 institutionalized mentally retarded
adults) with a conﬁrmed diagnosis of one of the categories of
ASD listed in the Diagnosis and Statistical Manual of Mental
Diseases (DSM-IV). All patients were studied using the
ADI-R to deﬁne a speciﬁc category of ASD and the Wechsler
Intelligence Scale for Children or Wechsler Adult Intelligence
Scale. These assessments provide a measure of general, verbal
and performance IQ as well as analysis of multiple factorial
components of cognitive functioning. We also use the Leiter
International Performance Scale-Revised and the Raven Pro-
gressive Matrices in the non-verbal patients. All patients had
an extensive evaluation by neurologists and clinical geneticists
along with an intensive laboratory workup including standard
karyotyping, fragile X molecular testing, subtelomeric and tar-
geted MLPA assays (homemade panel designed to detect
genomic duplications/deletions of speciﬁc regions associated
with ASD and mental retardation: 1p36, 2q37, 7q11.23,
15q11–q13, 17p11.2, 16p11.2, 22q11.2 and 22q13.3), as
well as metabolic and brain image studies in some cases
when clinically indicated (Gener et al. submitted). All subjects
participated after informed consent was obtained from their
families or other legal caregivers. The study was approved
by the medical ethical committees of the centers involved.
Blood samples were obtained under institutional review
board-approved informed consent, and genomic DNA was
extracted by the salting out method using the Puregenew
DNA Puriﬁcation Kit (Gentra Systems). Parental samples
were also obtained from the available parents who gave
informed consent.
Controls
DNA samples from 100 population control individuals
matched for population ancestry (Spanish anonymous blood
donors) were used to prepare reference pools (50 males and
50 females) for hybridization experiments. DNAs from 52
control individuals (27 males and 25 females) were used in
order to deﬁne polymorphic changes in DNA dosage in
aCGH experiments.
CGH arrays
We used three different microarray platforms. The ﬁrst screen-
ing was performed using a homemade BAC array containing
5442 large insert DNA fragments (BACs) with a global cover-
age of 23% of the euchromatic genome and higher probe
density in genomic regions presumed hot-spots for rearrange-
ments, named HSBA (23) (see Supplementary Material,
Table S5, for more detailed information). To conﬁrm the
different variants detected with HSBA, we used two commer-
cial arrays, either an oligoarray (Agilent 44K or 244K) or an
SNP array (Illumina 370K). We performed hybridization
experiments and subsequent analyses of aCGH as described
previously in detail (23), and we followed the manufacturer’s
recommendations for the SNP array. We used the PennCNV
(19 November 2008 version, sample option) and CNV
partition software for the analysis of the Illumina 370K
array data (59).
Multiplex ligation probe ampliﬁcation
A total of 100 ng of genomic DNA from each sample was sub-
jected to MLPA using synthetic probes designed to target the
speciﬁc CNV detected by aCGH, at least one locus per CNV.
Oligonucleotide sequences for MLPA at the analyzed loci are
described in the Supplementary Material, Table S6. The
MLPA reactions were performed essentially as described pre-
viously and products were analyzed on an ABI PRISM 3100
genetic analyzer according to manufacturers’ instructions.
For quantitative analysis, trace data were retrieved using the
accompanying software (GeneScan, Applied Biosystems).
Each MLPA signal was normalized and compared with the
corresponding mean peak height obtained from ﬁve control
DNA samples.
Gene ontology analyses
To obtain a general overview of the most relevant key func-
tions represented in our data set, the genes located in the ident-
iﬁed CNVs were used for ontology and biofunction analyses.
We used the IPA software (http://www.ingenuity.com),
along with two additional resources freely available: the Con-
sensusPathDB (http://cpdb.molgen.mpg.de) and the KEGG
Pathway Database (http://www.genome.ad.jp/kegg/pathway.
html) (60). We performed a core analysis to categorize the
genes on the basis of their locations and their reported or
suggested biochemical, biological and molecular functions.
In the ConsensusPathDB, we checked the functional annota-
tion of the gene list by using the pathway-based set options.
Statistical analysis
Fisher’s exact test for count data and Pearson’s x
2 test with
simulated P-value (based on 10 000 replicates) were applied
when appropriate for measuring signiﬁcant differences in
gene copy number frequencies or pathway representation. In
all cases, statistical signiﬁcance was considered for corrected
P-values ,0.05. Differences were assessed with the x
2 test
using resampling. The Z-test was used in inference to deter-
mine whether the number of genes affecting relevant pathways
in ASD was statistically signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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